Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8179640 | 0.93 | MEN1 (0.67) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL7647926 | 0.89 | KMT2A (0.55) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL7648688 | 0.82 | KMT2A (0.50) | MEN1KMT2APOLBAKR1C3SMN1; SMN2 | |
| SCHEMBL8187563 | 0.82 | SMN1; SMN2 (0.54) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL24221019 | 0.80 | LMNA (0.63) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL7646320 | 0.78 | MEN1 (0.67) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL23271159 | 0.77 | LMNA (0.72) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL853015 | 0.77 | LMNA (0.72) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL17007431 | 0.77 | LMNA (0.58) | MEN1KMT2APOLBLMNAALDH1A1 | |
| SCHEMBL7651531 | 0.76 | GAA (0.51) | MEN1KMT2ALMNAALDH1A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | claimed |
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | disclosed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000000472-A1 | 5-HT7 RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | MEN1 1132/4885KMT2A 3243/4885POLB 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.